GTBP Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 13:53):

Stats
Today's Volume	8 682.00
Average Volume	13 608.00
Market Cap	4.63M
EPS	$-2.19 ( 2024-04-04 )
Next earnings date	( $-2.70 ) 2024-05-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.600
ATR14	$0.106 (3.21%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-11	Breen Michael Martin	Buy	200 000	Common Stock
2023-08-11	Ohri Manu	Buy	200 000	Common Stock
2023-08-11	Ohri Manu	Buy	200 000	Common Stock
2023-08-11	Ohri Manu	Sell	200 000	Common Stock
2023-06-16	Casamento Charles J	Buy	500 000	Option to purchase Common Stock

INSIDER POWER
83.39
Last 90 transactions
Buy: 52 855 774 \| Sell: 22 501 893

GT Biopharma, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

GT Biopharma, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-5.64

FY	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-5.64

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-19.30

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.06

Financial Reports:

No articles found.

GT Biopharma, Inc.

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.